Category: Stocks

Bypass These Pitfalls to (Major) Profits in Bioscience

investing in experimental drugs can be an object lesson in volatility.
As the drugs progress toward FDA approval or denial, the stock prices of the companies backing them can be in for the same volatile ride.
As the drugs progress toward FDA approval or denial, the stock prices of the companies backing them can be in for the same volatile ride.
A stock’s surge or decline is often premised on general assumptions about the likelihood of FDA approval.
But within specific bioscience sectors, that likelihood varies… widely.
That’s why I wanted to navigate through some types of drugs that generate a lot of enthusiasm but often crash before delivery.
That way you can avoid some of the downside risk of this often lucrative market…

Read more →

5 Numbers That Should Scare Facebook Investors

The fact of the matter of the matter is that Facebook shares will almost certainly disappoint investors who participate in the IPO, because the prices being bandied about simply don’t reflect the numerous risks that are also part and parcel of the business. Here are five numbers that highlight some of those significant risks:

Read more →